Thanks to the backing of governments and policymakers the world over, electronic health records have become more prevalent in the last few years – but what are the main benefits of the syst
Increasing interest in real-world evidence (RWE) across all stakeholder groups has the industry buzzing about its current role in clinical trials and the potential impact of expanded use.
Although real world evidence (RWE) is a hot topic in pharma right now, many still question whether it is acceptable to be used in regulatory decision making.
A new study has found that blood thinning drugs improve outcomes for all heart failure patients, regardless of whether they already have atrial fibrillation (AF).
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
